Key facts
- This page summarizes John E. Imhoff's Form 4 filing for GUIDED THERAPEUTICS INC (GTHP).
- 6 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 07 Apr 2026, 15:14.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Other
Other
Other
Conversion of derivative security
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Award
Conversion of derivative security
Additional SEC filing notes
Footnote F1
One-fourth of the shares subject to the award vested on March 10, 2026; the remaining shares will vest monthly, starting on June 10, 2026, subject to the reporting person's continued service on each such date, until the award is fully vested on March 10, 2029.
Footnote F2
These shares were issued for payment of accrued dividends on the reporting individual's Series F preferred stock, at a conversion price of $0.2773.
Footnote F3
On March 26, 2026, Mr. Imhoff converted 10 shares of Series F preferred stock into 40,000 shares of common stock. The Series F preferred stock had a stated value of $1,000 and $0.25 conversion price.
Footnote F4
On March 31, 2026, Dr. Imhoff converted $11,019.18 outstanding under a September 25, 2025 Convertible Promissory Note into 157,417 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $1,019.18 of accrued interest. Following the reported conversion, $110,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note.